MD, Albert Einstein College of Medicine
Montefiore Medical Center
Fellowship, Reproductive Endocrinology & Infertility
Mount Sinai Hospital
Obstetrics & Gynecology
Beilin Y, Bodian C, Mukherjee T, Andres L, Vincent RD, Hock DL, Sparks AE, Munson AK, Minnich ME, Steinkampf MP, Christman GM, McKay RS, Eisenkraft J. The use of propofol, nitrous oxide, or isoflurane does not affect the reproductive success rate following gamete intrafallopian transfer (GIFT): a mul. Anesthesiology 1999 Jan; 90(1): 36-41.
BACKGROUND: Whether anesthetic agents administered during gamete intrafallopian transfer (GIFT) affect reproductive outcome is controversial. This multicenter pilot trial and survey had two purposes: to evaluate the effect of propofol, nitrous oxide, midazolam, and isoflurane on pregnancy outcome after GIFT, and to determine if a larger prospective, randomized study is warranted. METHODS: A written invitation was mailed to all 50 fertility programs in the United States that are members of the Society for Assisted Reproductive Technology and perform more than 30 GIFT procedures per year. They were invited to contribute information from the medical records of women who underwent GIFT during the calendar years 1993 and 1994. They were asked to document whether propofol, nitrous oxide, midazolam, a potent inhaled anesthetic agent was used during the GIFT procedure; if the woman became pregnant; and if she delivered at least one live neonate. RESULTS: Seven medical centers participated and contributed data from 455 women. The clinical pregnancy rate (number of pregnancies/total number of GIFT procedures) and the delivery rate (number of women who delivered at least one live baby/total number of GIFT procedures) were 35% and 32%, respectively. A statistically significant difference could not be found in the clinical pregnancy or delivery rates between those women who received propofol, nitrous oxide, midazolam, or isoflurane during GIFT and those who did not. CONCLUSIONS: No agent-related differences in pregnancy rates were found when propofol, nitrous oxide, isoflurane, or midazolam was used as part of the anesthetic technique for GIFT. Therefore, a more extensive prospective trial does not appear to be warranted.
Levy B, Mukherjee T, Hirschhorn K. Molecular cytogenetic analysis of uterine leiomyoma and leiomyosarcoma by comparative genomic hybridization. Cancer Genet Cytogenet 2000 Aug; 12(1): 1-8.
Ali SS, Elliott WH. Bile acids. XLVII. 12alpha-Hydroxylation of precursors of allo bile acids by rabbit liver microsomes. Biochimica et biophysica acta 1975 Nov; 409(2).
Alekseeva IG, Lapina GP, Tulovskaia ZD, Izmaĭlova VN. [Structure formation in interphase adsorption layers of lysozyme at liquid boundaries]. Biofizika; 20(4).
Rose AH. Growth and handling of yeasts. Methods in cell biology 1975; 12.
Donahoo CA. If you like variety, become an orthopedic surgeon's assistant. Nursing 1976 Jan; 6(1).
Caras I, Shapiro B. Partial purification and properties of microsomal phosphatidate phosphohydrolase from rat liver. Biochimica et biophysica acta 1975 Nov; 409(2).
Smith RJ, Bryant RG. Metal substitutions incarbonic anhydrase: a halide ion probe study. Biochemical and biophysical research communications 1975 Oct; 66(4).
A prospective, randomized, placebo, controlled study on the effect of cyclic intermittent etidronate therapy on bone mineral density changes associated with six months of gonadotropin releasing hormone agonist treatment.. Am J Obstet Gynecol 1996; 8.
The effect of prolonged gonadotropin releasing hormone agonist therapy on the histopathology of uterine leiomyomata. . Journal of Gynecologic Surgery;.
Prophylactic albumin for severe ovarian hyperstimulation syndrome.. Fertil Steril (Letter) 1996 July;.
The effect of hydrosalpinx fluid on murine embryogenesis: a case for prophylactic salpingectomy. . Fertil Steril 1996; 66:851-3.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Mukherjee is not currently required to report Industry relationships.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.